A new endocrine treatment for patients with congenital adrenal hyperplasia is being recommended for marketing in Europe after achieving positive results in a Phase 3 study of 122 patients with the disease. The European Medicines Agency delivered the positive opinion on 26 March, ahead of a decision on marketing authorisation by the European Commission.
